Meiji Seika Pharma

Japan - TokyoCDMO (Contract Manufacturing)

Focus: Meiji Seika Pharma is a Japanese CDMO and specialty pharmaceutical company spanning contract manufacturing, generics, and proprietary drug development across immunology, infectious diseases, and neurology. The company operates as part of the broader Meiji Seika Kaisha conglomerate with significant manufacturing and R&D capabilities.

Immunology Infectious Diseases Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Meiji Seika Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Meiji Seika Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Arbekacin Sulfate

Infection Due to Resistant Organism

N/A

Clinical Trials (1)

NCT01659515Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

N/A

Help build intelligence for Meiji Seika Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a diversified pipeline with 13 active programs spanning Phase 1-3, including late-stage assets in infectious disease (cefepime/nacubactam) and immunology (belumosudil, DMB-3115)
Exposure to multiple therapeutic areas (immunology, infectious diseases, neurology) provides cross-functional skill development and disease expertise breadth
Part of an established Japanese conglomerate with CDMO capabilities, offering stability and manufacturing-focused career trajectories

Watch Out For

Currently zero active job openings suggests limited hiring momentum and potential constraints on career mobility or team expansion
Heavy Phase 1 concentration (7 of 13 programs) indicates early-stage portfolio with limited near-term revenue catalysts or commercial scaling opportunities
Limited public visibility on financials, R&D spending, and strategic direction makes it difficult to assess long-term company stability and career growth trajectory

Generated by Claude from Meiji Seika Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DMB-3113

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT02927353A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

Phase 1

DMB-3111

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT02100917Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

Phase 1

ME1100 inhalation solution

Healthy

Phase 1

Clinical Trials (1)

NCT01961830Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers

Phase 1

ME1111 solution

Onychomycosis

Phase 1

Clinical Trials (1)

NCT01841996Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Phase 1

OP0595

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02134834A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

Phase 1

ME1100 inhalation solution

Healthy

Phase 1

Clinical Trials (1)

NCT01907776Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers

Phase 1

ME1100 inhalation solution

Pneumonia, Bacterial

Phase 1

Clinical Trials (1)

NCT02459158A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia

Phase 1

ME1111 Solution, Low strength

Onychomycosis

Phase 2

Clinical Trials (1)

NCT02022215Efficacy and Safety Study of ME1111 in Patients With Onychomycosis

Phase 2

co-administration of cefepime and nacubactam

Complicated Urinary Tract Infection

Phase 3

Clinical Trials (1)

NCT05905055P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Phase 3

Asenapine

Schizophrenia

Phase 3

Clinical Trials (1)

NCT01142596Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

Phase 3

Belumosudil

Lung Transplant Rejection

Phase 3

Fluvoxamine maleate

Obsessive Compulsive Disorder

Phase 3

co-administration of cefepime and nacubactam

Complicated Urinary Tract Infection

Phase 3

Clinical Trials (1)

NCT05887908Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

Phase 3

DMB-3115

Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Clinical Trials (1)

NCT04785326Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 3